AbbVie

News

AbbVie braces for impact of Humira biosimilars in Europe

AbbVie looks set to lose several billion dollars in revenue from Humira, as its soon to expire European patent presents healthcare providers with a major cost-saving opportunity for a biosi

News

AbbVie takes option on Argenx's cancer immunotherapy

ARGX-115 is still in preclinical development

Views & Analysis

Practical tool to address real patient information needs

Everyone benefits when patients are informed and empowered – we know that. Adherence rates are higher, services run smoother, outcomes are stronger.

Sales & Marketing

J&J tops the pharma market cap charts – but for how long?

Data and analytics firm GlobalData has tracked the market cap and performance of the top 25 pharma companies for the first quarter of this year – and there are some notable changes compared

News

AbbVie's Orilissa gets FDA nod as Humira competition looms

AbbVie needs new drugs as its mega-blockbuster Humira won’t bring in billions forever – and after the embarrassing withdrawal of an MS drug earlier this year it has managed to get a substan

News

AbbVie raises hopes for blood cancer patients

AbbVie has filed its Venclexta (venetoclax) for a new use that it hopes could change the treatment of one of the most aggressive cancers – acute myeloid leukaemia (AML).

AbbVie braces for impact of Humira biosimilars in Europe

AbbVie takes option on Argenx's cancer immunotherapy

Practical tool to address real patient information needs

J&J tops the pharma market cap charts – but for how long?

AbbVie's Orilissa gets FDA nod as Humira competition looms

AbbVie raises hopes for blood cancer patients

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks